M
MARSHMALLOW
Botanical Name: | Althaea officinalis |
Family: | Malvaceae |
Plant Parts Used: | Root, leaf |
PRESCRIBING INFORMATION
Actions | Marshmallow root and leaf:demulcent, urinary demulcent, emollient | |
Potential Indications | Based on appropriate evaluation of the patient, practitioners should consider prescribing marshmallow root in formulations in the context of: Based on appropriate evaluation of the patient, practitioners should consider prescribing marshmallow leaf in formulations in the context of: | |
Contraindications | None known. | |
Warnings and Precautions | The absorption of other medications taken simultaneously with marshmallow root may be retarded.1 Simultaneous ingestion of drug medications and marshmallow root should therefore be avoided. | |
Interactions | None known. | |
Use in Pregnancy and Lactation | No adverse effects expected. | |
Side Effects | None expected if taken within the recommended dose range. | |
Dosage | Root: | |
Dose per day* | Dose per week* | |
3-6 ml of 1:5 tincture | 20-40 ml of 1:5 tincture | |
3-6 ml of 1:5 glycetract | 20-40 ml of 1:5 glycetract | |
Leaf: | ||
Dose per day** | Dose per week** | |
3-6 ml of 1:2 liquid extract | 20-40 ml of 1:2 liquid extract |
* This dose range is extrapolated from the British Pharmaceutical Codex 1949, the British Herbal Pharmacopoeia 1983, the British Herbal Compendium 1992, and the author’s education and experience.
** This dose range is extrapolated from the British Herbal Pharmacopoeia 1983 and the author’s education and experience.
SUPPORTING INFORMATION
1 Scientific Committee of the European Scientific Cooperative on Phytotherapy [ESCOP]. ESCOP monographs: Althaeae radix. Argyle House, Gandy Street, Exeter, Devon, EX4 3LS, United Kingdom: European Scientific Cooperative on Phytotherapy, ESCOP Secretariat, March 1996.
2 Felter HW, Lloyd JU. King’s American dispensatory, ed 18. Portland: Eclectic Medical Publications, 1905. rev 3, reprinted 1983
3 British Herbal Medicine Association’s Scientific Committee. British herbal pharmacopoeia. Bournemouth: BHMA, 1983.
4 Bisset NG, editor. Herbal drugs and phytopharmaceuticals. Stuttgart: Medpharm Scientific Publishers, 1994.
5 Schmidgall J, Schnetz E, Hensel A. Planta Med. 2000;66(1):48-53.
6 Muller-Limmroth W, Frohlich HH. Fortschr Med. 1980;98:95-101.
7 Nosal’ova G, et al. Pharmazie. 1992;47:224-226.
8 Scheffer J, Konig W: 3rd Phytotherapy Congress, Lubeck-Travemunde, October 3-6, 1991, abstract P9.
9 Mascolo N, et al. Phytother Res. 1987;1:28-31.
10 Beaune A, Balea T. Therapie. 1966;21:341-347.
11 Blumenthal M, et al, editors. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin: American Botanical Council, 1998.
MEADOWSWEET
Botanical Name: | Filipendula ulmaria |
Family: | Rosaceae |
Plant Part Used: | Aerial parts |
PRESCRIBING INFORMATION
Actions | Antacid, antiinflammatory, mild urinary antiseptic, astringent | |
Potential Indications | Based on appropriate evaluation of the patient, practitioners should consider prescribing meadowsweet in formulations in the context of: • Genitourinary tract disorders, such as cervicitis, vaginitis, leukorrhea, cystitis, and dysuria (5) | |
Contraindications | None known. | |
Warnings and Precautions | Meadowsweet contains salicylates and should be avoided or used with caution in patients with salicylate sensitivity. | |
Interactions | None known. Given the experimental anticoagulant effect, meadowsweet should be used with caution if patients are taking warfarin. | |
Use in Pregnancy and Lactation | No adverse effects expected. | |
Side Effects | None expected if taken within the recommended dose range. | |
Dosage | Dose per day* | Dose per week* |
3-6 ml of 1:2 liquid extract | 20-40 ml of 1:2 liquid extract |
* This dose range is extrapolated from the British Herbal Pharmacopoeia 1983, the British Herbal Compendium 1992, and the author’s education and experience.
SUPPORTING INFORMATION
The following book was referred to in the compilation of the pharmacologic and clinical informationMills S, Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. Edinburgh: Churchill Livingstone, 2000.
1 British Herbal Medicine Association’s Scientific Committee. British herbal pharmacopoeia. Bournemouth: BHMA, 1983.
2 Felter HW, Lloyd JU. King’s American dispensatory, ed 18. Portland: Eclectic Medical Publications, 1905. rev 3, reprinted 1983
MILK THISTLE
Other Common Name: | St. Mary’s thistle |
Botanical Name: | Silybum marianum, Carduus marianus# |
Family: | Compositae |
Plant Part Used: | Fruit (sometimes referred to as seed) |
PRESCRIBING INFORMATION
Actions | Hepatoprotective, hepatic trophorestorative, antioxidant, choleretic | |
Potential Indications | Based on appropriate evaluation of the patient, practitioners should consider prescribing milk thistle in formulations in the context of: • Nonalcoholic and alcoholic liver damage or disease, including abnormal liver function and fatty liver (4a) | |
Contraindications | None known. | |
Warnings and Precautions | None required. | |
Interactions | None known. | |
Use in Pregnancy and Lactation | No adverse effects expected. | |
Side Effects | Drug monitoring studies in 1995 investigating the concentrated extract (silymarin) indicated that adverse effects were recorded in 1% of patients, mainly as mild gastrointestinal complaints. A mild laxative effect was occasionally observed with milk thistle preparations. Two cases of anaphylactic shock have been reported. | |
Dosage | Dose per day* | Dose per week* |
4.5-8.5 ml of 1:1 liquid extract | 30-60 ml of 1:1 liquid extract | |
4.5-8.5 ml of 1:1 glycetract | 30-60 ml of 1:1 glycetract | |
Extracts providing quantified levels of silymarin-silybin are recommended. Ideally, aqueous ethanol extracts should contain not less than 25 mg/ml silymarin, and aqueous glycerol extracts should contain not less than 10 mg/ml silymarin.
![]() Stay updated, free articles. Join our Telegram channel![]() Full access? Get Clinical Tree![]() ![]() ![]() |